In the BioHarmony Drug Report Database
Givosiran
Givlaari (givosiran) is an oligonucleotide pharmaceutical. Givosiran was first approved as Givlaari on 2019-11-20. It has been approved in Europe to treat hepatic porphyrias. Givlaari’s patents are valid until 2034-10-03 (FDA).
Trade Name
|
Givlaari |
|---|---|
Common Name
|
givosiran |
ChEMBL ID
|
CHEMBL4297760 |
Indication
|
hepatic porphyrias |
Drug Class
|
Image (chem structure or protein)
